Imagion Biosystems today announced “Notice of change of interests of substantial holder — IBX.”
View Form 604 Notice of change of interests of substantial holder — IBX.
Quarterly Activity Report – Quarter ending 31 December 2023
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal